Patent

Overview

Honigman’s Patent practice is a group of attorneys with extensive experience, specific technical knowledge, and years of industry involvement. The majority of our team possesses advanced technical degrees, hands-on experience as research scientists or engineers, and/or backgrounds in-house at global corporations across a range of industries. Our lawyers and patent agents are trusted partners who work hand-in-hand with our clients to design, execute, and enhance patent portfolios in a straightforward, comprehensive, and cost-efficient manner. We assist our clients in maximizing business competitiveness by securing and safeguarding commercially relevant patents that coincide with their business goals.

The distinctive hallmark of our Patent practice is that we anticipate and understand technical and legal developments across the United States and abroad and thereby are able to plan the most effective business strategies to maximize patent life cycles in relevant markets.

Our Patent practice group attorneys represent clients ranging from Fortune 100 companies to start-ups, universities, and independent inventors across the U.S., with particular technical strengths in the software, electrical, mechanical, and chemical areas, as well as in the life sciences industry.

Our services include:

   
Patent Preparation and Prosecution
   
  • Patent portfolio strategy and management in the U.S. and worldwide
  • Established track record in preparing and procuring medical, chemical, biotech, computer, electrical, and mechanical patents
  • Post-allowance patent practice (oppositions, patent term adjustments, and patent term extensions)  
   
Consulting and Opinions  
   
  • Patent opinions (validity, freedom-to-operate, and infringement)
  • Patent due diligence in the context of product development, patent enforcement, and corporate transaction
  • Competitor intelligence (competitor review and monitoring)
   
Licensing and Transactional Matters
   
  • Patent licensing
  • Patent aspects of research and development agreements
  • University and government licensing
  • Patent aspects of mergers and acquisitions
       

Technical Strengths

Honigman is particularly known for its technical strength in the life sciences, software, electrical, mechanical, and chemical industries. Our intimate knowledge of these industries is derived from having technical and in-house experience with leading pharmaceutical, medical device, chemical, and biotechnology companies as well as experience working with individuals working on advanced research, technologies, and processes to secure protections and to ensure the global marketability of their work product.

Honigman’s intellectual property attorneys help clients protect and defend mission-critical assets, as well as help position our clients to competitive advantage in the global marketplace. Our work in the life sciences spans a wide range of applications and disciplines—from pharmaceuticals, medical devices, and medical imaging to treatment protocols, genetics, stem cell research, vaccines, and more.

We possess particular strengths in the following areas:

   
Life Sciences  
   
  • Medical devices 
  • Medical imaging 
   
Pharmaceuticals 
   
  • Compositions of matter  
  • Small molecules 
  • Biologics 
  • Solid forms  
  • Drug combinations 
  • Bioactive metabolites 
  • Pharmaceutical formulations 
  • Treatment methods 
  • Synthetic processes 
  • Diagnostic kits  
   
Biology 
   
  • Cell and molecular
  • Gene therapy  
  • Genomics
  • RNA interference 
  • Stem cell technology 
  
   
Mechanical   
   
  • Automotive components  
  • Footwear and apparel  
  • Mechanical devices
  • Optical systems 
   
Electrical   
   
  • Communication systems 
  • Memory systems
  • Compilers 
  • Mobile and telecommunications  
  • Data storage systems 
  • Networking systems 
  • Sensor systems 
  • Semiconductors
   
Robotics   
   
  • Artificial intelligence 
  • Autonomous and semi-autonomous navigation systems 
  • Behavioral systems  
  • Mobility platforms
  • Sensor systems 
  • Vision systems 
   
Software 
   
  • Analytics and algorithms 
  • Augmented reality 
  • Cloud computing
  • Enterprise software solutions 
  • Internet applications 
  • Mobile applications 
   
Chemical   
   
  • Electrochemistry 
  • Electroplating
  • Process chemistry 
  • Solid state chemistry  
  • Analytical chemistry 
  • Polymers 

Material Science
  • Batteries
  • Fuel cells
  • Nanotechnology
  

News & Resources

News

  • Gregory A. Morris, Ph.D, is quoted in Law360 article "PTAB Practice Guide Changes Will Aid Patent Owners"
    (August 14, 2018)
     
  • Jeffrey A. Chelstrom is featured in the Chicago Tribune article “Honigman Continues To Strengthen Its Intellectual Property Practice”
    (May 31, 2016)
     
  • Brandon C. Griffith’s move to Honigman is mentioned in the Detroit Free Press section “Business leaders in the news”
    (September 19, 2015)
     
  • Noel E. Day, Ph.D., is quoted in the Bloomberg article "Attorneys Tell PTO of Patent Eligibility Uncertainty"
    (September 15, 2015)
     
  • Eric J. Sosenko’s move to Honigman is mentioned in the National Law Journal article “Laterals”
    (May 4, 2015)
     
  • Eric J. Sosenko’s move to Honigman is featured in the American Lawyer article “Half-Dozen K&L Gates Partners Decamp, Plus More Lateral Moves”
    (April 21, 2015)
     
  • Noel E. Day, Ph.D., is quoted in the Bloomberg article “Life Sciences Patents Get Needed Boost Under PTO Rule Responding to Novartis
    (January 23, 2015)
     
  • Noel E. Day, Ph.D., is quoted in the Bloomberg article “PTO’s Interim Revised Eligibility Guidance Spurs Short-Lived Optimism in Life Sciences”
    (December 18, 2014)
     
  • Noel E. Day, Ph.D. is quoted in the Reuters Legal article “Q&A: Does new USPTO guidance leave uncertainty on what’s patent-eligible?”
    (December 17, 2014)
     
  • Noel E. Day, Ph.D., is extensively quoted in the Intellectual Property Magazine article “New ‘straightforward' USPTO section 101 seeks public guidance”
    (December 17, 2014)
     
  • Brett A. Krueger is quoted in the Law 360 article “5 Tips For Getting Software Patents Approved Post-Alice”
    (September 2, 2014)
     
  • Anna M. Budde’s move to Honigman is featured in Bloomberg’s “Law Firm News”
    (August 5, 2014)
     
  • Honigman’s Intellectual Property Department is highlighted in the Yahoo! Finance article “Honigman ranks among the country’s top ten law firms for intellectual property patent work in BTI’s ‘IP Outlook’ report”
    (July 31, 2014)
     
  • Brett A. Krueger is quoted in the National Law Journal article “‘Alice Corp.’ Is Already Making its Mark on Patent Law”
    (July 16, 2014)
     

Press Releases

Events

  • Antibodies in an Anti-Patent Climate: Weathering the Storm of Stricter Written Description and Enablement Requirements, 15th Advanced Summit on Life Sciences Patents, American Conference Institute (ACI), New York, NY
    February 28, 2017
  • A Primer on IP Basics and Regulatory Fundamentals Relative to Small-Molecule Drugs, Paragraph IV Disputes Master Symposium: Hatch-Waxman Boot Camp, American Conference Institute (ACI), Chicago, IL
    September 19-20, 2016
  • Demystifying IPRs for Effective Use in the Biosimilars Landscape, 7th Annual Summit on Biosimilars, American Conference Institute (ACI), New York, NY
    June 13-15, 2016
  • Prosecuting the Unexpected Ratio: Advanced Lessons in Patent Prosecution and Claim Drafting, Webinar
    April 28, 2016
  • Pharmaceutical Patent Invalidity Challenge Score Card: District Courts v. The PTAB, 10th Annual Paragraph IV Disputes, American Conference Institute (ACI), New York, NY
    April 25-26, 2016
  • Industry Liaison and Innovation: Drug Development Boot Camp, Intensive Educational Program Designed for Researchers and Pharmacologists, Dalhousie University, Halifax, Nova Scotia, CA
    April 2016
  • A Patent Exhaustion Doctrine for the High Tech Global Economy Age, 10th Annual Patent Law Institute, Practising Law Institute (PLI), New York, NY
    April 14, 2016
  • Protecting your Business’ Intellectual Property: Patents & Copyrights, Michigan Chamber of Commerce
    December 16, 2015
  • PTAB Update: Where Are We After 3 Years of Orange Book Patent Challenges?, NJIPLA 29th Annual Pharmaceutical / Chemical Patent Practice Update, American Conference Institute (ACI), Iselin, NJ
    October 2015
  • Practitioner's Perspective on 101 as Applied to Biotech Applications, United States Patent and Trademark Office: Biotechnology, Chemical and Pharmaceutical Partnership Meeting, Detroit, MI
    September 14, 2015
  • Litigation Update, Electronic Computer Patent Law Summit, American Intellectual Property Law Association, Dallas, TX
    June 2015
  • Protecting Intellectual Property in the Global Marketplace, Medical Technologies: Growth Strategies for Global Marketplace, Global Business Club of Mid-Michigan, Lansing, MI
    March 31, 2015
  • Exploring the Parallel World of IPR Proceedings, 5th Advanced Summit on Medical Device Patents, American Conference Institute (ACI)
    March 4, 2015
  • Throwing the Baby Out with the Bath Water: Where Universities Fit in the Debate on NPEs and Patent Reform, New York City Bar Association, New York, NY
    November 20, 2014
  • Identifying Patents Which May be Ripe For Challenges of Invalidity and Non Infringement: Offensive and Defensive Strategies For Brand Names and Generics, Paragraph IV Disputes Master Symposium, American Conference Institute (ACI), Chicago, IL
    October 3, 2013
  • Patent Trolls and the New Tolls they try to Charge the Good People in the Large Apartment Business, Home Builders Association of Southeastern Michigan, Detroit, MI
    June 27, 2013
  • America Invents Act First-to-File Changes: What Happens Now?, Webinar
    February 27, 2013
  • Augmented Reality Patents and Patent Litigation, AR Dirt Podcast
    February 22, 2013
  • America Invents Act Comes to Campus: The Impact on Commercialization and Technology Transfer Offices, BIO International Convention, Boston, MA
    June 18-21, 2012
  • Life Science Industry Breakout Session, 2012 Intellectual Property Law Spring Seminar, Intellectual Property Law Section, State Bar of Michigan and the Institute of Continuing Legal Education
    March 26, 2012
  • 2012 Intellectual Property Law Spring Seminar, Institute of Continuing Legal Education and Intellectual Property Law Section, State Bar of Michigan, East Lansing, MI
    March 26, 2012
  • The Effects of the New Patent Rules on Prior Art, Chicago Bar Association's Intellectual Law Property Committee, Chicago, IL
    January 24, 2012
  • Crucial Issues Concerning Induced and Contributory Infringement, National CLE Conference: Intellectual Property, Snowmass, CO
    January 6, 2012
  • The Leahy-Smith America Invents Act: A Further Look into "First-to-File", Webinar
    November 17, 2011
  • 10 Current Topics of Interest for In-House Counsel, Honigman and the Association of Corporate Counsel - Michigan Chapter, Troy, MI
    November 15, 2011
  • Impact of U.S. Patent Reform on Biotechnology, MichBio Expo, Grand Rapids, MI
    November 2, 2011
  • Updated and Revised AIPLA Model Patent Jury Instructions, AIPLA Annual Meeting, Washington, DC
    October 21, 2011
  • Gene patenting - Why do we care? Recent developments in Australia and the United States, Biotechnology and Environmental Biology Discipline Seminar, Royal Melbourne Institute of Technology University, Melbourne, Australia
    August 2011
  • Taming the Most Expensive Lawsuits: Controlling Costs in Patent Litigation, 7th Circuit Bar Association Annual Meeting, Milwaukee, WI
    May 16, 2011
  • The Intersection Between Patent and Competition Law: Are You Headed for a Collision?, Intellectual Property Law Association of Chicago, Chicago, IL
    May 1, 2010
  • IP Enforcement in Global Markets (US Case Study), China Pharmaceutical Law Summit, Shanghai, China
    April 8-9, 2010
  • Effective Global Intellectual Property Due Diligence, MichBio Expo, Kalamazoo, MI
    November 4, 2009
  • Global Intellectual Property Due Diligence, BIO International Convention, Atlanta, GA
    May 20, 2009
  • Survey Evidence in Trademark Disputes Roundtable, International Trademark Association and Honigman Miller Schwartz and Cohn LLP, Bloomfield Hills, MI
    January 27, 2009
  • Understanding the Other Side of the Table: Perspectives from commercial licensees, National Institutes of Health, NIAID, Rockville, MD
    November 18, 2008
  • Potential Rule Changes at the USPTO: Implications for European Practitioners, IP Pharma Europe Summit 2008, Montreux, Switzerland
    October 23-25, 2008
  • Overcoming the Challenges Posed By Proposed Changes to Markush (Alternatives) Practice, Pharma Biotech Summit 2008, Philadelphia, PA
    May 28-30, 2008
  • Regulatory Updates, Pharma Biotech Summit 2008, Philadelphia, PA
    May 28-30, 2008
  • Effectively Maintaining Patent Protection and Enforcement in Light of Upcoming Regulations, Pharma Biotech Summit 2008, Philadelphia, PA
    May 28-30, 2008
  • Is Michigan behind life sciences?, Michigan Leaders Speak
    March 12, 2008
  • IP Protocol for the Central Corridor Licensing Partnership, Hosted by the Consulate General of Canada, Government of Canada, in participation with several universities from Canada and the United States, Detroit, MI
    February 26, 2008
  • Aligning Your Patent Timing Strategies with Business Objectives in Order to Maximize Your Patent Lifecycle, American Conference Institute's Pharma/Biotech Patent Claim Drafting & Prosecution: Creative Strategies for a Rapidly Evolving Patent Landscape, New York
    February 25-26, 2008
  • Sweepstakes, Raffles and Contests, Legal Pitfalls to Avoid When Running Contests and Promotions, Brighton Chamber of Commerce
    November 2007
  • Technology Development for Extramural Programs, Division of Acquired Immunodeficiency Syndrome, National Institute of Allergy and Infectious Diseases, NIH, DHHS, Bethesda, MD
    May 4, 2007
  • NIAID’s Technology Transfer and Intellectual Property Resources, Division of Intramural Research, Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, NIH, DHHS, Bethesda, MD
    November 14, 2006
  • Franchising 101, Legal Issues to Consider Before You Franchise Your Business, Brighton Chamber of Commerce
    January 2006
  • Introduction to Patent Basics, Southwest Michigan Innovation Center
    May 2004
  • Intellectual Property Basics, Pfizer Research University, Kalamazoo, MI
    December 2003
  • Going Global – Some Things To Consider, A Discussion on Expanding a Trademark Portfolio Overseas, International Trademark Association
    October 2002
  • CTM – Basics of Community Trademark Law, International Trademark Association
    February 2001
  • Inhibition of NF-kB Reduces Cellular Proliferation and Foci Formation in Breast Carcinomas and Glioblastomas, 29th Annual Meeting, American Society for Cell Biology, Washington, D.C.
    December 11-15, 1999
  • Unzipping Dispersed Fluorescence Spectra of Acetylene: Intramolecular Vibrational Redistribution Trends, Molecular Dynamics Workshop, Telluride, Colorado
    July 1995
  • Intramolecular Vibrational Redistribution in Acetylene, Ohio State University 50th International Symposium on Molecular Spectroscopy, Columbus, OH
    June 1995
  • Patent File Wrapper Estoppel—Recent Trends, 1995 Spring Seminar, Intellectual Property Law Section, State Bar of Michigan, Lansing, MI
    Spring 1995
  • Molecular Dynamics in Acetylene: Effective Hamiltonian Models and Optimal Intermediate States for Dispersed Fluorescence Spectra (Rao Prize: Most Outstanding Student Presentation), Ohio State University 49th International Symposium on Molecular Spectroscopy, Columbus, OH
    June 1994
  • Corporate Patent Strategies For Protecting Technology, 1994 International Seminar, Detroit, MI
    April 19, 1994
  • Collaborative Learning in the Classroom, Training Session for Chemistry Teaching Assistants, MIT
    Fall & Spring 1994
  • How to be an Effective Recitation Instructor, Training Session for Chemistry Teaching Assistants, Massachusetts Institute of Technology, Cambridge, MA
    Fall & Spring 1992
  • What is X-ray Crystallography?, Seminar Series, Hope College
    Fall 1990

Publications

  • Expert Q&A on Recent Developments with Orange Book-Listed Patent Challenges at the PTAB
    (August 2016)
     
    Practical Law Intellectual Property & Technology
  • Expert Q&A on Orange Book-listed Patent Challenges at the PTAB
    (September 2015)
     
    Practical Law Intellectual Property & Technology
  • Do Not End Up with an Unenforceable Patent – It's Your Hard-Earned Patent
    (November 2014)
     
    MichBio - Biolink Legal Column
  • Post-Octane and Highmark, Will District Courts Flex Their Muscle on Fee-Shifting?
    (2014)
     
    Bloomberg BNA: Patent, Trademark & Copyright Journal
  • Protecting Biotech and Pharma Innovations Under New USPTO Guidelines
    (September 2, 2014)
     
    Life Science Leader
  • What is Patentable? 'Natural' Limits in PTO Guidelines
    (July 22, 2014)
     
    Corporate Counsel
  • The CD6 T lymphocyte surface glycoprotein: Functional evidence for multiple ligands
    (December 12, 2012)
     
    Arthritis Rheum, 37:S376
  • The Changing Tide of Patentability Standards and Filing Timelines for Biotechnologies
    (2012)
     
    The Impact of Recent Patent Law Cases and Developments, Aspatore: Inside the Minds™
  • Recent Developments in the Law of Joint Inventorship
    (2011)
     
    Developing a Patent Strategy, Aspatore: Inside the Minds
  • Comparative effectiveness research has implications for medical device and pharmaceutical patenting
    (July 9, 2010)
     
    Michigan Lawyers Weekly, Volume 24, No. 35, Page 2
  • Deciding the future of gene patents
    (June 3, 2010)
     
    West Michigan Business Review, MLive.com
  • Deciding the future of gene patents
    (June 3, 2010)
     
    West Michigan Business Review, MLive.com
  • What Healthcare Reform Means for Mich. Pharma and Medical Companies
    (April 2010)
     
    LabWork, Powered by MiBiz
  • Biomarker Patent Strategies – Opportunities and Risks
    (2010)
     
    Biomarkers in Drug Development: A Handbook of Practice, Application, and Strategy
  • Lifting the R&D Organizational Veil under the American Recovery Reinvestment Act
    (October 2009)
     
    Michigan Biosciences LINK, P. 8-9
  • Lifting the R&D Organizational Veil under the American Recovery Reinvestment Act
    (September 1, 2009)
     
    Michigan Biosciences LINK
  • Trade secret misappropriation
    (2009)
     
    A Practical Guide to Life Science Companies: Commercializing & Protecting Innovation, Ed. John R. Wetherell, 587-605
  • Patent Protection Versus Trade Secrets
    (2009)
     
    A Practical Guide to Life Science Companies: Commercializing & Protecting Innovation, Ed. John R. Wetherell, 606-624
  • What is a trade secret?
    (2009)
     
    A Practical Guide to Life Science Companies: Commercializing & Protecting Innovation, Ed. John R. Wetherell, 567-586
  • Molecular Heterogeneous Catalysis: A Single-Site Zeolite-Supported Rhodium Complex for Acetylene Cyclotrimerization
    (September 7, 2007)
     
    Chemistry: A European Journal, Volume 13, Issue 26, pages 7294-7304
  • Genome-Wide Linkage of 77 Families From the African American Hereditary Prostate Cancer Study
    (January 1, 2007)
     
    The Prostate, Volume 67, Issue 1, pages 22-31
  • Evidence from NMR and EXAFS Studies of a Dynamically Uniform Mononuclear Single-Site Zeolite-Supported Rhodium Catalyst
    (January 16, 2006)
     
    Angewandte Chemie International Edition, Volume 45, Issue 4, pages 574-576
  • Survey: Merck KGaA v. Integra Lifesciences I, Ltd., 125 S. Ct. 2372
    (Fall 2005)
     
    University of San Francisco Intellectual Property Law Bulletin, 10 No. 1 Intell. Prop. L. Bull.103 (Westlaw)
  • A Patent Portfolio Strategy for Entrepreneurs
    (Spring 2005)
     
    Germeshausen Center Newsletter
  • Development of a Long-acting Insulin Analog Using Albumin Fusion Technology
    (2005)
     
    54 (1) Diabetes 251-258
  • Patent Infringement and 'Reach-Through' royalty claims on pharmaceutical products discovered using patented tools: New decision weighs against such claims
    (January 16, 2004)
     
    Pillsbury Winthrop Client Alert
  • The Face of the Patent is not the 'Whole Story’: Determining Effective Life of a Pharmaceutical Patent in the United States
    (2004)
     
    World Patent Information, 26, 4
  • K-562 cells lack MHC class II expression due to an alternatively spliced CIITA transcript with a truncated coding region
    (2003)
     
    Leukemia Research, 27: 1027-1038
  • Metal-mediated Allylation of Mucohalic Acids: Facile Formation of y-allylic a, β-unsaturated Butyrolactones
    (2003)
     
    Tet. Lett., 44, 5579
  • Genetic Epidemiology of Complex Disorder
    (2002)
     
    Fox Chase Cancer Center Scientific Report
  • Cross reaction of mammalian Elongation Factor-2 to anti-double stranded DNA autoantibodies
    (2001)
     
    Clin. Immunol., 98(2):293-300
  • Use of Fluorescently Labeled DNA and a Scanner for Eletrophoretic Mobility Shift Assays
    (2001)
     
    30(s) Biotechniques 504-506
  • Protein Kinase Cα Plays a Critical Role in Mannosylerythritol Lipid-induced Differentiation of Melanoma B16 Cells
    (2001)
     
    The Journal of Biological Chemistry, 43: 39903-39910
  • The Role of NF-kB in Breast Carcinoma and Glioblastoma Cell Lines
    (2001)
     
    Thesis Publication, Dwight B. Waldo Library, General Stacks, Western Michigan University, Department of Biological Sciences
  • Simultaneous Flow Cytometric Measurement of K-562 Megakaryocytic Differentiation and CD56+ Large Granular Lymphocyte Cytotoxicity
    (2001)
     
    J. Immunol. Methods, 253: 37-44
  • Simultaneous Detection of RNA and Protein by in situ Hybridization and Immunological Staining
    (2001)
     
    The Journal of Histochemistry and Cytochemistry, 49: 1-7
  • Unanticipated Economic Gains and the ADA: Assistive Technology Patent Trends
    (2000)
     
    Peter D. Blanck, (ed.) Northwestern University Press
  • 2,444 Coriolis Perturbations
    (2000)
     
    Journal of Chemical Physics, 199, 265
  • Evidence of Disability After Daubert v. Dow
    (1999)
     
    Psychology, Public Policy and Law, 5, 1
  • Assistive Technology Patenting Trends and the Americans with Disabilities Act
    (1999)
     
    Behavioral Sciences and the Law, 17, 47
  • Fourier Transform Infrared Spectroscopic Detection of Low-Frequency Vibrational Modes of Photosystem II Acceptors and the Oxygen-Evolving Complex
    (1999)
     
    Biochemistry
  • Pure Bending Dynamics in Acetylene
    (1998)
     
    Journal of Chemical Physics, 109, 121
  • Numerical Pattern Recognition in Acetylene Dispersed Fluorescence Spectra
    (1998)
     
    Journal of Chemical Physics, 108, 7100
  • Anomalously Simple IVR in the Acetylene So State
    (1998)
     
    Journal of Chemical Physics, 109, 3831
  • Protection of Information Products: Balancing Commercial Reality and the Public Domain
    (1998)
     
    Comment, University of Cincinnati Law Review, 67:1
  • Antibodies to dsDNA cross react with Apolipoprotein A1
    (1998)
     
    Arthritis & Rheumatism, S:253
  • The Economics of the Americans with Disabilities Act, Part II
    (1998)
     
    Notre Dame Journal of Philosophy, Public Policy, and Law, 12, 9
  • Expression and purification of recombinant CAP37 (rCAP37), a multifunctional inflammatory mediator
    (April 6-9, 1997)
     
    Experimental Biology, FASEB J. 1997:11(3)
  • Intramolecular Dynamics in the Frequency Domain
    (1997)
     
    Advances in Chemical Physics, Vol. 101. John Wiley and Sons, Inc., 463-490
  • Discrimination of European and Australian Globodera rostochiensis and G. pallida pathotypes by high performance capillary electrophoresis
    (1997)
     
    Fundamental Applied Nematology, 20:187-193
  • The influence of the MAPK pathway on T cell lineage commitment
    (1997)
     
    Immunity, 7(5):609-18
  • Highly Excited 12C2H2 in the So State: Complementarity of Absorption and Dispersed Fluorescence Spectra
    (1996)
     
    Journal of Chemical Physics, 105, 11357-11360
  • The Effects of Triplet Perturbations on Photophysical Processes in the S1 State of Acetylene
    (Accepted 1996)
     
    Journal of Chemical Physics
  • Role of the CD6 glycoprotein in antigen-specific and autoreactive responses of cloned human T lymphocytes
    (1996)
     
    Immunology, 88(4):537-543
  • Characterization of Immunorelated peptides to Porcidin P1
    (1995)
     
    Immunology and Cell Biology, 73(6):505-510
  • The Acetylene So Surface: From Dispersed Fluorescence Spectra to Polyads to Dynamics
    (1995)
     
    Ber. Bunsen Phys. Chem., 99, 555-560
  • Dispersed Fluorescence Spectrum of Acetylene: Recognition of Polyads and Test of Multiresonant Effective Hamiltonian Model
    (January 1, 1995)
     
    Journal of Chemical Physics, 100, 7797-7809
  • Antibacterial peptides from porcine polymorphonuclear neutrophils
    (1995)
     
    Immunology and Cell Biology, 73(1):38-43
  • ABC’s of Patent Licensing
    (September 1994)
     
    Michigan Technology Update
  • Transcriptional regulation of CD6 expression on human T lymphocytes by phorbol ester
    (1994)
     
    J Immunol, 153:1-9
  • Evidence for multiple CD6 ligands on cells interacting with T-lymphocytes
    (1994)
     
    Clin Res, 42:232A
  • The sevenmaker gain-of-function mutation in p42 MAP kinase leads to enhance signaling and reduced sensitivity to dual specificity phosphatase action
    (1994)
     
    FEBS Letters, 352:201-205
  • Activation of human T cells through CD6: Functional effects of a novel anti-CD6 monoclonal antibody and definition of four epitopes of the CD6 glycoprotein
    (1993)
     
    Int Immunol, 5:783-792
  • An anti-CD2 monoclonal antibody that both inhibits and stimulates T cell activation recognizes a subregion of CD2 distinct from known ligand-binding sites
    (1993)
     
    Cell Immunol, 150:235-246
  • Zirconium Compounds of Hexamethyldisiloxane
    (1993)
     
    Organometallics, 12, 338
  • Antimicrobial peptides from porcine neutrophils
    (1993)
     
    Journal of Leukocyte Biology, 73: S67
  • Role of the CD6 surface structure in human T cell activation and autoreactivity
    (1993)
     
    Revista Espanola de Rheumatologia, 20:49 (suppl 1)
  • Anti-CD6 monoclonal antibodies inhibit the antigen specific and autoreactive responses of cloned human T lymphocytes
    (1993)
     
    Tissue Anogens, 42:440
  • The Structure, Function and Regulation of the Human Lymphocyte Surface Antigen CD6
    (1992)
     
  • Function of CD6 in human T Cell activation and autoreactivity
    (1992)
     
    Clin Res, 40(2): 152A
  • Antimicrobial peptides from porcine polymorphonuclear neutrophils
    (1992)
     
    Australian Microbiologist, 13: 157
  • Characterization of a third functional epitope of CD6
    (1991)
     
    FASEB J, 5:7665A